DEVELOPMENT OF ADENO ASSOCIATED VIRUS/ADENOVIRUS HYBRID

除了想要的基因，成功的基因治疗还需要 合适的载体或载体以引入转基因 进入牢房。用于宿主细胞的长期转化或 有机体，把转基因放在它所在的环境中 与细胞基因组同步复制是必要的。人类 细小病毒，腺相关病毒。(这需要腺病毒来 乘法)，一直被用作向量，因为它从未被 被确认为人类病原体，尽管约90%的成年人患有 针对病毒的抗体。腺相关病毒(AAV)整合 在19号染色体上的特定位置进入人类基因组并可以 即使在未分裂的细胞中也整合它的DNA(尽管在较低的 频率)。当前的AAV载体具有一定的局限性：1)它们 难以在高浓度下生产；2)它们具有 转基因大小的能力有限；3)目前 它们不会以特定于站点的方式进行集成。腺病毒 (AD)也被用作载体。因为广告载体不会 在细胞内自主整合或复制，它们能够 仅在短暂的基础上转变。然而，它是相对的 容易产生大量的广告载体和载体 转基因能力几乎是目前AAV的两倍 向量。该项目的目标是构建一种杂交病毒。 AAV和Ad之间的载体将具有所需的属性 两者都是。可以产生大量的载体，并且 转基因可以整合到19号染色体上的特定位置 用于永久表达。为了创造转基因的杂交载体， 侧翼是关键的AAV末端序列和AAV rep基因 站点特定集成所需的内容将合并到 将站点分离为Ad DNA的主干。媒介病毒将是 在细胞培养中对两者进行测试，以确定其功能 在分子水平和动物模型中评估宿主的反应， 具备长期转型的能力和能力。

In addition to the desired gene, successful gene therapy requires an appropriate vehicle or vector for introduction of the transgene into the cell. For long term transformation of the host cell or organism, placing the transgene into a context in which it is replicated in synchrony with the cell genome is necessary. The human parvovirus, adeno-associated virus. (which requires adenovirus to multiply), has been used as a vector, because it has never been identified as a human pathogen, even though about 90% of adults have antibodies to the virus. Adeno-associated virus (AAV) integrates into the human genome at a specific site on chromosome 19 and can integrate its DNA even in non dividing cells (albeit at a lower frequency). Current AAV vectors have certain limitations: 1) they are difficult to produce in high concentration; 2) they have a limited capacity for the size of the transgene; 3) as currently made, they do not integrate in a site specific manner. Adenovirus (Ad) has also been used as a vector. Because Ad vectors do not integrate or replicate autonomously within the cell, they are able to transform only on a transient basis. However, it is relatively easy to produce large amounts of the Ad vector and the carrying capacity for the transgene is almost twice that of current AAV vectors. The goal of this project is to construct a hybrid virus vector between AAV and Ad which would have the desirable properties of both. Large amounts of the vector could be produced and the transgene could be integrated into a specific site in chromosome 19 for permanent expression. To create the hybrid vector the transgene, flanked by critical AAV terminal sequences, and the AAV rep gene required for site specific integration would be incorporated at separate sites into a backbone of Ad DNA. The vector virus will be tested both in cell culture in order to characterize its function at the molecular level and in animal models to assess host response, clearance and ability to transform in a long term manner.